Patents
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2007
05/30/2007CN1972714A Methods of treating autoimmune and inflammatory diseases
05/30/2007CN1972713A Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
05/30/2007CN1972712A Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
05/30/2007CN1972711A Therapeutic vaccine and method of use
05/30/2007CN1972710A Methods and compositions comprising bacteriophage nanoparticles
05/30/2007CN1972707A Treatment of conditions involving demyelination
05/30/2007CN1972703A Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
05/30/2007CN1972671A Microspheres comprising protein and showing injectability at high concentrations of said agent
05/30/2007CN1970774A Porcine alpha-interferon recombinant adenovirus and its construction method and application
05/30/2007CN1970764A Porcine beta-interferon recombinant adenovirus and its construction method and application
05/30/2007CN1970573A Neutrality monoclonal antibody 3E1 for resisting ricin, its preparation method and uses
05/30/2007CN1970082A Preparation process of autogenous high-immunity serum for treating post-weaning multi systemic wasting syndrome of baby pig
05/30/2007CN1970081A Avian influenza virus marking vaccine, preparation process and application thereof
05/30/2007CN1970080A Method for producing virus vaccine by using suspended Vero cell
05/30/2007CN1970074A Application of beta-protein inhibitor in preparation of medicament for treating genetic correlated disease
05/30/2007CN1318596C Vectors based on recombinant defective viral gene group, and their use in formulation of vaccines
05/30/2007CN1318592C O type foot and mouth disease virus DNA vaccine and its preparing method
05/30/2007CN1318591C Immune tbid gene and its coded protein and application
05/30/2007CN1318589C Method for preparing mammal cell kinetin synthetic inhibitory factor
05/30/2007CN1318580C Mass preparation of SARS virus capable of meeting the production of inactivated vaccine and inactivation method
05/30/2007CN1318576C Targeted cytolysis of HIV-infected cells by chimerical CD4 receptor bearing cells
05/30/2007CN1318573C Mycobacterium smegmatis preparation and use thereof
05/30/2007CN1318450C Modified/chimeric super-antigens and their use
05/30/2007CN1318449C Application of anti SARS specificity IgY in preparation dor preventing and treating SARS
05/30/2007CN1318447C Tumor antigen peptides originating in cyclophilin B
05/30/2007CN1318446C Transferrin receptor protein of Moraxella
05/30/2007CN1318092C Immunity treatment composition containing antibody-cytokine fusion protein mediated and angiogenesis inhibitor
05/30/2007CN1318091C Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases
05/30/2007CN1318089C Use of botulinum toxin for treatment of articular pathologies
05/30/2007CN1318023C Chemically-defined non-polymeric valency platform molecules and conjugates thereof
05/29/2007US7223858 Truncated aggrecanase molecules
05/29/2007US7223854 Transfecting or infecting cells and culturing; purified polypeptide, for use in diagnosis
05/29/2007US7223852 Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
05/29/2007US7223846 Urocortin proteins and uses thereof
05/29/2007US7223842 screening human patients to determine those not at risk of developing retinoblastoma and thus not requiring conventional examinations to be performed; immunization-produced antibody
05/29/2007US7223838 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/29/2007US7223836 Peptides for chlamydophila pneumoniae vaccine and diagnosis
05/29/2007US7223834 Assays and peptide substrate for determining aggrecan degrading metallo protease activity
05/29/2007US7223743 Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
05/29/2007US7223741 nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1
05/29/2007US7223600 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination
05/29/2007US7223594 Immunogens; replication-defective; antibodies; host cells; kits
05/29/2007US7223585 Viral purification methods
05/29/2007US7223584 Genome which overexpresses G protein to increase apoptosis in infected cells
05/29/2007US7223571 Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
05/29/2007US7223565 for drug screening interleukins; expression in bacteria, yeast, plant, insect, and animal cells; genetic engineering
05/29/2007US7223563 Nucleic acids; diagnosing and treating hypophosphatemic disorders; diagnosing tumor induced osteomalacia
05/29/2007US7223553 Immunoassays for everolimus
05/29/2007US7223542 Diagnosing cancer via determining concentration of marker polypeptides; genetic vaccines; antiproliferative/antitumor agents
05/29/2007US7223535 Using epitopic amino acid sequences to detect/diagnose hepatitis A viral infection; immunoassay
05/29/2007US7223412 Staphylococcal enterotoxin SEC-SER, expression vector and host cell, production method thereof, and manufacturing method of vaccine
05/29/2007US7223411 Administering a mutated herpesvirus having a mutation in genes encoding a protein essential for viral genome replication to render the herpesvirus replication defective; effecting an antibody subclass shift of IgG2a/IgG upon in vivo administration
05/29/2007US7223410 Inactivated respiratory syncytial viral vaccines
05/29/2007US7223409 Nucleic acid linked to a mammalian expression promoter that is suitable for producing and expressing capside, E1, E2, E3 and 6K structural proteins encoded by the 26S genomic virus RNA.
05/29/2007US7223408 Human papillomavirus E6 and E7 polypeptides, mutant polypeptide retains 30% of the immunogenicity of an isolated polypeptide comprising human wild-type papillomavirus E6 and E7
05/29/2007US7223407 Immunogens; water-in-oil emulsions; oil-in-water emulsions; vaccines; freeze drying
05/29/2007US7223399 administering the toxin directly to a blood vessel, especially following a cardiovascular procedure.
05/29/2007US7223398 Population of conjugate molecules of an allergen and a polynucleotide comprising an immunostimulatory sequence; polynucleotide conjugated, or attached, to antigens
05/29/2007US7223397 Administering an agent which upregulates the expression of a cellular target; administering a dose of an immunotoxin directed against the upregulated cellular target
05/29/2007US7223396 Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
05/29/2007US7223395 Blocking leukocyte emigration and inflammation by interfering with CD99/HEC2
05/29/2007US7223394 Human antibodies that bind human TNFα
05/29/2007US7223393 Monoclonal antibodies for use in the prevention and treatment of cell proliferative and skin disorders; immunotherapy; antitumor agents
05/29/2007US7223392 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
05/29/2007US7223388 Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance and immunogenicity; antiproliferative disorders
05/29/2007CA2268758C Immunogenic detoxified mutant e. coli lt-a toxin
05/24/2007WO2007059528A2 Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
05/24/2007WO2007059360A2 Oral use of specific antibodies for intestinal health
05/24/2007WO2007059242A1 Low-density lipoprotein receptor-related protein 2 clears amyloid-beta peptide a cross the blood-brian barrier via apolipoprotein j
05/24/2007WO2007059234A1 Method for the treatment of pdgf-d related diseases using anit-pdgf-dd antibodies
05/24/2007WO2007059188A1 Method for treating joint damage
05/24/2007WO2007059135A2 Methods of treating alzheimer's disease
05/24/2007WO2007059115A1 Anti-sepsis conjugate vaccine
05/24/2007WO2007059082A1 Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
05/24/2007WO2007058823A2 Anti-egfr antibodies
05/24/2007WO2007058625A1 Toxin-antitoxin system and applications thereof
05/24/2007WO2007058587A1 A compound comprising an autoantigenic peptide and a carrier with a mhc binding motif
05/24/2007WO2007058235A1 Fusion protein and use thereof for pharmaceutical purposes
05/24/2007WO2007058194A1 Inhibitor of cytotoxic t cell induction
05/24/2007WO2007057763A2 Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
05/24/2007WO2007057670A1 Nidogen/snep-iike molecule
05/24/2007WO2007057582A1 Composition comprising a colloidal synthetic bioresorbable vector and a viral vector
05/24/2007WO2007057062A1 Human bocavirus and methods of diagnosis and treatment
05/24/2007WO2007056870A1 Methods and compositions for pharmacologically controlled targeted immunotherapy
05/24/2007WO2007056858A1 Anti-alpha2 integrin antibodies and their uses
05/24/2007WO2007056847A1 Stabilizing formulations for recombinant viruses
05/24/2007WO2007028574A3 Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
05/24/2007WO2007028259A3 Antigens for vaccination against and detection of mycoplasma suis
05/24/2007WO2007028041A3 Loading of cells with antigens by electroporation
05/24/2007WO2007020078A3 Rotavirus vaccine inducing heterotypic cross protection
05/24/2007WO2007015935A9 Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
05/24/2007WO2007014743A3 Cd33-specific single-chain immunotoxin and method of use
05/24/2007WO2007008463A3 Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
05/24/2007WO2006135912A3 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
05/24/2007WO2006116192A3 Irta-1 antibodies and their uses
05/24/2007WO2006100681A3 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
05/24/2007WO2006071997A3 Treatment for cutaneous metastases
05/24/2007WO2006029089A3 Tetrahydrocannabinoid- protein conjugates for the production of antibodies for the detection of tεtrahydrocannabinoid components in saliva
05/24/2007WO2005016952A3 Polyvalent immunogen
05/24/2007WO2005013891A3 Vaccines using pattern recognition receptor-ligand:lipid complexes